Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiology of ITP. All treatment strategies for ITP attempt...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/916 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849409384595062784 |
|---|---|
| author | S. G. Zakharov T. A. Mitina A. V. Zakharova O. P. Madzyara I. N. Kontievskii R. V. Vardanyan E. V. Kataeva Yu. B. Chernykh L. L. Vysotskaya L. V. Ivanitskiy Yu. Yu. Chuksina O. R. Zhuravlev N. V. Gorgun Z. M. Kharasova E. V. Trifonova K. A. Belousov Z. R. Tekeeva |
| author_facet | S. G. Zakharov T. A. Mitina A. V. Zakharova O. P. Madzyara I. N. Kontievskii R. V. Vardanyan E. V. Kataeva Yu. B. Chernykh L. L. Vysotskaya L. V. Ivanitskiy Yu. Yu. Chuksina O. R. Zhuravlev N. V. Gorgun Z. M. Kharasova E. V. Trifonova K. A. Belousov Z. R. Tekeeva |
| author_sort | S. G. Zakharov |
| collection | DOAJ |
| description | Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiology of ITP. All treatment strategies for ITP attempt to increase platelet count and reduce the risk of bleeding complications. Corticosteroids remain the most commonly used first-line therapy for ITP, but their long-term use is limited due to the development of severe complications. Today the new treatment methods including the use of thrombopoietin receptor agonists (TPO-RA) romiplostim, eltrombopag and avatrombopag with a number of advantages over standard therapy are of great interest. These drugs are recommended for use in the second-line therapy and show high efficacy in patients with ITP, particularly in real clinical practice. In most cases TPO-RA provide stable and long-term remission of the disease, allowing you to reduce or discontinue the use of glucocorticosteroids and avoid splenectomy. Many studies of the mechanism of action, efficacy and toxicity of TPO-RA have been performed. the research results significantly expand our knowledge about these agents. This review provides comparative data of the TPO-RA safety and the main aspects of their clinical use. The features of the new drug avatrombopag, recently approved for use in the Russian federation, are described. the overview presents the advantages and limitations of each drug, possible adverse events and methods for their control. |
| format | Article |
| id | doaj-art-30d95f9a80694e7ca526cd07cc2bf0e3 |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2024-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-30d95f9a80694e7ca526cd07cc2bf0e32025-08-20T03:35:32ZrusABV-pressОнкогематология1818-83462413-40232024-04-0119210911710.17650/1818-8346-2024-19-2-109-117752Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopeniaS. G. Zakharov0T. A. Mitina1A. V. Zakharova2O. P. Madzyara3I. N. Kontievskii4R. V. Vardanyan5E. V. Kataeva6Yu. B. Chernykh7L. L. Vysotskaya8L. V. Ivanitskiy9Yu. Yu. Chuksina10O. R. Zhuravlev11N. V. Gorgun12Z. M. Kharasova13E. V. Trifonova14K. A. Belousov15Z. R. Tekeeva16M.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteUnited Hospital with Outpatient Department, Administrative Department of the President of the Russian FederationM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteM.F. Vladimirskiy Moscow Regional Research Clinical InstituteImmune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiology of ITP. All treatment strategies for ITP attempt to increase platelet count and reduce the risk of bleeding complications. Corticosteroids remain the most commonly used first-line therapy for ITP, but their long-term use is limited due to the development of severe complications. Today the new treatment methods including the use of thrombopoietin receptor agonists (TPO-RA) romiplostim, eltrombopag and avatrombopag with a number of advantages over standard therapy are of great interest. These drugs are recommended for use in the second-line therapy and show high efficacy in patients with ITP, particularly in real clinical practice. In most cases TPO-RA provide stable and long-term remission of the disease, allowing you to reduce or discontinue the use of glucocorticosteroids and avoid splenectomy. Many studies of the mechanism of action, efficacy and toxicity of TPO-RA have been performed. the research results significantly expand our knowledge about these agents. This review provides comparative data of the TPO-RA safety and the main aspects of their clinical use. The features of the new drug avatrombopag, recently approved for use in the Russian federation, are described. the overview presents the advantages and limitations of each drug, possible adverse events and methods for their control.https://oncohematology.abvpress.ru/ongm/article/view/916immune thrombocytopeniathrombopoietin receptor agonistromiplostimeltrombopagavatrombopag |
| spellingShingle | S. G. Zakharov T. A. Mitina A. V. Zakharova O. P. Madzyara I. N. Kontievskii R. V. Vardanyan E. V. Kataeva Yu. B. Chernykh L. L. Vysotskaya L. V. Ivanitskiy Yu. Yu. Chuksina O. R. Zhuravlev N. V. Gorgun Z. M. Kharasova E. V. Trifonova K. A. Belousov Z. R. Tekeeva Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia Онкогематология immune thrombocytopenia thrombopoietin receptor agonist romiplostim eltrombopag avatrombopag |
| title | Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia |
| title_full | Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia |
| title_fullStr | Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia |
| title_full_unstemmed | Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia |
| title_short | Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia |
| title_sort | complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia |
| topic | immune thrombocytopenia thrombopoietin receptor agonist romiplostim eltrombopag avatrombopag |
| url | https://oncohematology.abvpress.ru/ongm/article/view/916 |
| work_keys_str_mv | AT sgzakharov complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT tamitina complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT avzakharova complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT opmadzyara complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT inkontievskii complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT rvvardanyan complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT evkataeva complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT yubchernykh complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT llvysotskaya complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT lvivanitskiy complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT yuyuchuksina complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT orzhuravlev complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT nvgorgun complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT zmkharasova complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT evtrifonova complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT kabelousov complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia AT zrtekeeva complicationsofthrombopoietinreceptoragoniststherapyinpatientswithimmunethrombocytopenia |